WANG A-ying, LV Tang-feng. Safety and Feasibility: Evaluation of the Application of Regional MSLN CAR-T-Cell Therapy in Patients With Malignant Pleural Disease, in Combination With the Anti-PD-1 Agent Pembrolizumab[J]. Journal of Evidence-Based Medicine, 2023, 23(5): 273-276. DOI: 10.12019/j.issn.1671-5144.2023.05.004
|
Citation:
|
WANG A-ying, LV Tang-feng. Safety and Feasibility: Evaluation of the Application of Regional MSLN CAR-T-Cell Therapy in Patients With Malignant Pleural Disease, in Combination With the Anti-PD-1 Agent Pembrolizumab[J]. Journal of Evidence-Based Medicine, 2023, 23(5): 273-276. DOI: 10.12019/j.issn.1671-5144.2023.05.004
|
WANG A-ying, LV Tang-feng. Safety and Feasibility: Evaluation of the Application of Regional MSLN CAR-T-Cell Therapy in Patients With Malignant Pleural Disease, in Combination With the Anti-PD-1 Agent Pembrolizumab[J]. Journal of Evidence-Based Medicine, 2023, 23(5): 273-276. DOI: 10.12019/j.issn.1671-5144.2023.05.004
|
Citation:
|
WANG A-ying, LV Tang-feng. Safety and Feasibility: Evaluation of the Application of Regional MSLN CAR-T-Cell Therapy in Patients With Malignant Pleural Disease, in Combination With the Anti-PD-1 Agent Pembrolizumab[J]. Journal of Evidence-Based Medicine, 2023, 23(5): 273-276. DOI: 10.12019/j.issn.1671-5144.2023.05.004
|
DownLoad: